The utility of the DDAVP challenge test in children with low von Willebrand factor.
作者信息
Archer Natasha M, Samnaliev Mihail, Grace Rachael, Brugnara Carlo
机构信息
Pediatric Hematology/Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.
Clinical Research Center, Boston Children's Hospital, Boston, MA, USA.
出版信息
Br J Haematol. 2015 Sep;170(6):884-6. doi: 10.1111/bjh.13331. Epub 2015 Mar 2.
Abstract
摘要
相似文献
1
The utility of the DDAVP challenge test in children with low von Willebrand factor.去氨加压素激发试验在血管性血友病因子水平低的儿童中的应用。
Br J Haematol. 2015 Sep;170(6):884-6. doi: 10.1111/bjh.13331. Epub 2015 Mar 2.
2
DDAVP: a useful alternative to blood components in moderate hemophilia A and von Willebrand disease.去氨加压素：中度甲型血友病和血管性血友病中血液成分的有效替代物。
J Pediatr. 1983 Feb;102(2):228-33. doi: 10.1016/s0022-3476(83)80526-5.
3
Evaluation of a rapid von Willebrand factor activity latex immuno assay for monitoring of patients with von Willebrand disease (VWD) receiving DDAVP or VWF replacement therapy.评估一种用于监测接受去氨加压素（DDAVP）或血管性血友病因子（VWF）替代治疗的血管性血友病（VWD）患者的快速血管性血友病因子活性乳胶免疫测定法。
Haemophilia. 2014 Jul;20(4):e304-10. doi: 10.1111/hae.12437. Epub 2014 Apr 24.
4
Biological and clinical response to desmopressin (DDAVP) in a retrospective cohort study of children with low von Willebrand factor levels and bleeding history.在一项回顾性队列研究中，观察到具有低血管性血友病因子水平和出血史的儿童对去氨加压素（DDAVP）的生物学和临床反应。
Thromb Haemost. 2010 Nov;104(5):984-9. doi: 10.1160/TH10-04-0220. Epub 2010 Sep 30.
5
Effectiveness of D-arginine vasopressin in von Willebrand's disease.
Curr Hematol Rep. 2005 Jan;4(1):1-2.
6
A personalized approach to the management of VWD.血管性血友病（VWD）管理的个性化方法。
Transfus Apher Sci. 2019 Oct;58(5):590-595. doi: 10.1016/j.transci.2019.08.009. Epub 2019 Aug 7.
7
Mild forms of von Willebrand disease: diagnosis and management.血管性血友病的轻型：诊断与管理
Curr Hematol Rep. 2003 Sep;2(5):373-80.
8
DDAVP in acquired von Willebrand syndrome associated with multiple myeloma.
Am J Hematol. 1986 Aug;22(4):421-9. doi: 10.1002/ajh.2830220412.
9
On the discrepant post-DDAVP increase of FVIII:C and von Willebrand factor in some patients with severe von Willebrand's disease.
Br J Haematol. 1995 Oct;91(2):512-3. doi: 10.1111/j.1365-2141.1995.tb05332.x.
10
Type 1 von Willebrand disease: application of emerging data to clinical practice.1型血管性血友病：新兴数据在临床实践中的应用
Haemophilia. 2008 Jul;14(4):685-96. doi: 10.1111/j.1365-2516.2008.01757.x. Epub 2008 May 23.
引用本文的文献
1
DDAVP response and its determinants in bleeding disorders: a systematic review and meta-analysis.去氨加压素反应及其在出血性疾病中的决定因素：一项系统评价和荟萃分析。
Blood. 2025 Apr 17;145(16):1814-1825. doi: 10.1182/blood.2024026804.
2
The role of Aurora-A in human cancers and future therapeutics.极光激酶A在人类癌症中的作用及未来治疗方法
Am J Cancer Res. 2020 Sep 1;10(9):2705-2729. eCollection 2020.
3
The spectrum and severity of bleeding in adolescents with low von Willebrand factor-associated heavy menstrual bleeding.青少年低血管性血友病因子相关重度月经过多的出血谱和严重程度。
Blood Adv. 2020 Jul 14;4(13):3209-3216. doi: 10.1182/bloodadvances.2020002081.
本文引用的文献
1
The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology.血管性血友病的诊断与管理：英国血友病中心医生组织指南，经英国血液学标准委员会批准。
Br J Haematol. 2014 Nov;167(4):453-65. doi: 10.1111/bjh.13064. Epub 2014 Aug 12.
2
Biological and clinical response to desmopressin (DDAVP) in a retrospective cohort study of children with low von Willebrand factor levels and bleeding history.在一项回顾性队列研究中，观察到具有低血管性血友病因子水平和出血史的儿童对去氨加压素（DDAVP）的生物学和临床反应。
Thromb Haemost. 2010 Nov;104(5):984-9. doi: 10.1160/TH10-04-0220. Epub 2010 Sep 30.
3
Post-tonsillectomy bleeding in children with von Willebrand disease: a single-institution experience.儿童 von Willebrand 病扁桃体切除术后出血：单中心经验。
Otolaryngol Head Neck Surg. 2010 May;142(5):715-21. doi: 10.1016/j.otohns.2010.01.029.
4
Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD.1型血管性血友病（VWD）中去氨加压素的反应受基因型和表型影响：欧洲MCMDM-1VWD研究结果
Blood. 2008 Apr 1;111(7):3531-9. doi: 10.1182/blood-2007-08-109231. Epub 2008 Jan 29.
5
Intranasal desmopressin (Octim): a safe and efficacious treatment option for children with bleeding disorders.鼻内去氨加压素（奥曲肽）：治疗出血性疾病儿童的一种安全有效的选择。
Haemophilia. 2007 Sep;13(5):548-51. doi: 10.1111/j.1365-2516.2007.01519.x.
6
Desmopressin (DDAVP) responsiveness in children with von Willebrand disease.
J Pediatr Hematol Oncol. 2003 Nov;25(11):874-9. doi: 10.1097/00043426-200311000-00010.
7
Evaluation of high concentration intranasal and intravenous desmopressin in pediatric patients with mild hemophilia A or mild-to-moderate type 1 von Willebrand disease.高浓度鼻内和静脉注射去氨加压素治疗轻度甲型血友病或轻度至中度1型血管性血友病患儿的疗效评估。
J Pediatr. 2002 May;140(5):595-9. doi: 10.1067/mpd.2002.123626.
8
High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A.高剂量去氨加压素鼻喷雾剂（施他宁）用于预防和治疗轻度甲型血友病、轻度或中度1型血管性血友病患者以及甲型血友病有症状携带者的出血。
Haemophilia. 2001 May;7(3):258-66. doi: 10.1046/j.1365-2516.2001.00500.x.
9
Management of von Willebrand disease: a survey on current clinical practice from the haemophilia centres of North America.
Haemophilia. 2001 May;7(3):235-41. doi: 10.1046/j.1365-2516.2001.00498.x.
Zotero 插件